Impact and Cost-Effectiveness of Hypothetical Strategies to Enhance Retention in Care within HIV Treatment Programs in East Africa  by Kessler, Jason et al.
Avai lable onl ine at www.sc iencedirect .comV A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 4 6 – 9 5 51098-3015$36.00 – s
Published by Elsevie
http://dx.doi.org/10
E-mail: Jason.Ke
* Address corresp
Avenue, VZ30, 6th Fjournal homepage: www.elsevier .com/ locate / jva lORIGINAL ARTICLES
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East Africa
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Scott Braithwaite, MD, MSc
Department of Population Health, New York University School of Medicine, New York, NY, USAA B S T R A C TObjectives: Attrition from care among HIV infected patients can lead
to poor clinical outcomes. Our objective was to evaluate hypothetical
interventions seeking to improve retention-in-care (RIC) for HIV-
infected patients in East Africa, asking whether they could offer
favorable value compared to earlier ART initiation.Methods: We used
a micro-simulation model to analyze two RIC focused strategies
within an East African HIV treatment program–“risk reduction,”
deﬁned as intervention(s) that decrease the risk of attrition from care;
and “outreach,” deﬁned as interventions that ﬁnd patients and relink
them with care. We compared this to earlier ART treatment as a
measure of the potential health beneﬁts forgone (e.g., opportunity
cost). Results: Reducing attrition by 40% at an average cost of $10 per
person remains a less efﬁcient use of resources compared to ensuring
full access to ART (cost- effectiveness ratio $1300 vs $3700) for ART
eligible patients. An outreach intervention had limited clinical beneﬁtee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2015.09.2940
ssler@nyumc.org.
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loor, New York, NY 10016, USA.in our simulation. If intervention costs areo$10 per person, however,
an intervention able to achieve a 40% (or greater) reduction in attrition
may be a cost-effective next implementation option following imple-
mentation of earlier ART treatment. Conclusions: Our results suggest
that programs should consider retention focused programs once they
have already achieved high degrees of ART coverage among eligible
patients. It is important that decision makers understand the epi-
demiology and associated outcomes of those patients who are
classiﬁed as lost to follow up in their systems prior to implementation
in order to achieve the highest value.
Keywords: Africa, cost-effectiveness analysis, health care utilization,
HIV/AIDS.
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Attrition from HIV treatment programs in sub-Saharan Africa,
estimated to be approximately 20% at 1 year after antiretroviral
therapy (ART) initiation [1–3], is an enormous challenge that
threatens the gains achieved as a result of the public health
scale-up of HIV care and treatment [4–6]. Attrition, often referred
to as “loss to follow-up”, does not provide information about an
individual’s true treatment or vital status.
Patients classiﬁed as “lost to follow-up” (LFTU) may 1) have
transferred their care to another facility, unbeknownst to the
original treatment site (often referred to as “silent transfer” or
“remains connected to care”) [7,8]; 2) be disengaged from care and
no longer on treatment; or 3) be dead. Studies that have physically
traced patients classiﬁed as LTFU have discovered high propor-
tions of patients in each of these three circumstances, with deaths
accounting for 20% to 60% of those who were successfully traced
[9–11]. High rates of death or connection to care among LTFUpatients could potentially lessen the beneﬁts of implementing
programs that aim to reduce disengagement because patients who
remain connected to care or who have died will not garner any
beneﬁt from such programs. Retention/re-engagement strategies
that discriminate between the possible circumstances of silent
transfer, death, and true disengagement from care [10,12,13] or
that can substantially reduce the rate of disengagement [14–18],
however, may have the potential to improve patient outcomes.
Therefore, interventions that seek to reduce disengagement or
identify, trace, and relink those patients who have become
disengaged from care in sub-Saharan Africa may provide favorable
value compared with other interventions designed to optimize
outcomes for HIV-infected patients.
Mindful of the importance of distinguishing between patients
who maintain a connection to care, those who have died, and true
losses to care, we sought to evaluate the impact of alternative
retention-in-care strategies in East Africa. In addition, we sought to
ascertain the cost-effectiveness of the best retention-in-careociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Table 1 – Key input parameters to computer simulation.
Parameter Estimate (range
considered)
Reference(s)
Characteristics of simulated cohort
CD4 count, mean  SD 287  242 AMPATH data
Age (y), mean  SD 39  9 AMPATH data
Mean ART adherence 70% Adjusted for
calibration
Loss to care probabilities
Probability of disengagement from clinic (per month) [LTFU] 0.4%–2.4%* (0.5–2.0) [3]
Relative risk of disengagement from clinic if pre-ART 2 [46–49]
Probability disengagement from care if disengaged from clinic 27% (16%–56%) [8,13,25,40]
Probability of identiﬁcation of disengagement 100% Assumption
Relative risk of treatment failure given disengaged from care 3.32 [50–54]
Intervention characteristics
Risk reduction intervention—Relative risk reduction on probability of
disengagement
40% (10%–90%) [14–18,26,27]
Cost of risk reduction intervention per person/month $10 ($1–$50) Assumption
Outreach intervention—Probability of tracing 56% [7,8,55]
Outreach intervention—Probability of relinkage following successful tracing 60% [12,56]
Costs, 2014 (US$)
Pre-ART HIV care (annually) 429 [57]
Care while on ﬁrst-line ART (annually) 740 [57]
Care while on second-line ART (annually) 1453 [57]
Mortality/inpatient hospitalization (per event) 220 [58]
AMPATH, Academic Model Providing Access to Healthcare; ART, antiretroviral therapy; LTFU, loss to follow-up (patient can be in one of three
mutually exclusive health states—1) alive and in care elsewhere, 2) alive and disengaged from care, 3) death which has been unrecognized).
* Range reﬂects dependence of probability of disengagement on time spent in care (i.e., higher rate of disengagement in the ﬁrst 6–12 mo of
clinical follow-up/treatment).
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uses for HIV-infected persons, in particular to expansion of ART
access.Methods
Overview
We expanded and recalibrated a previously developed stochastic
microsimulation HIV model to account for retention-in-care
dynamics [19]. We used this simulation to analyze the effective-
ness and value of implementing retention-in-care strategies
within a hypothetical East African HIV care and treatment
program. Model parameters were informed by data from East
African sources where possible (Table 1). We compared the scale-
up of these interventions with that of earlier ART provision as a
measure of the potential health beneﬁts forgone (e.g., opportu-
nity cost), which could be gained by applying resources to other
simultaneously resource-constrained decisions.
HIV Disease Progression Simulation
This model has been previously validated by a demonstration of
its ability to predict clinical data in several distinct clinical
cohorts [19–21]. Each simulated patient is assigned a CD4 count
and viral load (VL) from a relevant probability distribution
reﬂecting an East African population in care, and the model
tracks an individual’s CD4 count, VL, treatment status (on/off
ART), and ART regimen (two regimens assumed to be available)
over time, as well as the likelihood of experiencing an incident
symptomatic HIV/AIDS-related clinical event (e.g., opportunistic
infection) or dying of an HIV-related or HIV-unrelated event. ART
initiation is assumed to occur at a CD4 count of less than or equalto 200 cells/mm3. Although this does not reﬂect the current
World Health Organization (WHO) recommendation [22], it does
reﬂect a common situation in under-resourced programs [23,24].
Results were aggregated from large numbers of patient simula-
tions to obtain stable estimates of the outcomes.
Representation of LTFU, Disengagement, and Re-Engagement
in Simulation
Patients classiﬁed as LTFU have heterogeneous outcomes and
may have a wide array of root causes of attrition. To account for
this, we added representation of the following clinical/treatment
states to our computer simulation (Fig. 1).
A “disengaged from clinic” (LTFU) patient is one who has not
returned for follow-up care and treatment as requested and whose
vital status is uncertain. If a patient is disengaged from clinic, they
can be in one of three mutually exclusive health states: “Death, unrecognized”: The patient is deceased, but the
surveillance system did not detect this outcome or death
was not reported to the health facility. “Connected to care”: The patient transferred care to another
health facility or health provider, and this was either not
reported or incorrectly reported to the initial treating facility;
hence, the patient is incorrectly categorized as lost. It is
assumed that the patient is continuing to receive all relevant
medications and care. “Disengaged from care” (care interruption): The patient is
alive and no longer receiving care or treatment.
We simulate a cohort of HIV-infected persons initially in care.
Patients can remain engaged in care or can become disengaged
from clinic (LTFU) following one of two pathways. An individual
can suffer a mortality event, which is not ascertained by the health
Fig. 1 – Conceptual model of attrition from care and re-engagement in care and an intervention portfolio designed to mitigate
dropout from clinic and care within HIV treatment programs in sub-Saharan Africa. Cohort begins in HIV care and treatment
state at the start of simulation and can progress to a “disengaged from clinic” (LTFU [lost to follow-up]) state either through
death without appropriate surveillance (3 in ﬁgure) or through lost to clinic pathway (1 in ﬁgure). Patients considered LTFU as
classiﬁed by health facility reside in one of three mutually exclusive health states—unrecognized death, unreported transfer
of care, or disengaged from care. Patients who are transfers are assumed to continue on ART treatment. Patients disengaged
from care are assumed to be no longer compliant with ART or opportunistic infection prophylaxis. Disengaged patients will
return to care (4 in ﬁgure) if they experience a new symptomatic AIDS event. Transition probabilities between states are
represented by the following—Mt, mortality; 1, probability of disengagement from clinic; 2, probability of unreported transfer
given disengagement from clinic; 3, probability of death misclassiﬁcation; 4, return to care given disengaged from care; 5,
probability of being successfully traced given outreach intervention component available; 6, probability of being successfully
relinked to care given successful tracing; , complementary probability (e.g., 1-linked probability). Note. Not all state transitions
are represented in the ﬁgure for purposes of readability. For example, if patients are in unrecognized transfer state, they are
exposed to the same risks of death or disengagement as if they were located in original care and treatment state. Gray dotted
line boxes/arrows represent components (and their effects) of interventions designed to mitigate loss from HIV treatment
programs. (A) Strategies that act to reduce the likelihood that patients disengage from clinic. (B) Outreach strategy that acts to
trace, ascertain status of, and relink those patients categorized as disengaged from care back to the health system. ART,
antiretroviral treatment.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 4 6 – 9 5 5948facility where they receive care. As in earlier versions of this
simulation, mortality is closely associated with immune and
virologic status (i.e., untreated patients with high VLs and lower
CD4 counts have substantially higher mortality than do patients on
ART who have suppressed VLs and immune recovery). An individ-
ual can also transfer care to another health facility without this
information being captured by the initial facility. Such silent
transfers may be common in locales where robust health informa-
tion systems such as electronic medical records or “ART passports”
do not exist [8,25]. Finally, a patient may delink or disengage from
care and follow-up at the health facility but remain alive. Previous
work has suggested that the LTFU rate is inversely associated with
time spent in care, and this was adjusted for in the state transition
probabilities governing disengagement from clinic [3]. Given the
heterogeneity of LTFU rates reported in the literature, the out-
comes associated with patients classiﬁed as such, and the incom-
pletely understood relationship between these, we chose to model
the rates and probabilities of disengaging from clinic and the
likelihood of delinking from care independently.
Patients who remain engaged in care or who are LTFU but
remain connected to care experience the same likelihood of
future adverse outcomes (e.g., death or disengagement from
care). Patients who disengage/delink from care are assumed to
be no longer compliant with ART and have similar probabilities ofexperiencing an adverse outcome as any other patient not on
ART (controlling for immune and virologic status). We further
assume that patients who are disengaged from care will relink to
care on their own if they experience a symptomatic AIDS-related
event (more likely to occur once their CD4 count drops below 200
cells/mm3). The methods underlying the recalibration of this
simulation are described in detail in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2015.09.2940.
Representation of Alternative Retention-in-Care Strategies
We simulated alternative strategies exploring varying relative
emphases: 1) a risk reduction intervention that seeks to reduce
the chances of a patient from disengaging from clinic following
enrolment; 2) an outreach intervention that seeks to ﬁnd/ascer-
tain/trace the status of patients who are disengaged from clinic
and relink those who are disengaged from care. These compo-
nent strategies were operationalized as follows.
Risk Reduction
The risk reduction intervention attempts to reduce the likelihood
that any patient will disengage from clinic after enrolment. Many
interventions have been demonstrated to have an impact on the
rate of LTFU, and as such, wide uncertainty estimates
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and cost is based on a review of the literature including obser-
vational studies of interventions/strategies or cost-effectiveness
analyses of interventions that had an impact on disengagement
rates [14–18,26,27]. We explored wide plausible intervals for
estimates of intervention effectiveness (10%–90%) and cost ($1–
$50 per patient per month) within our sensitivity analyses to
represent the heterogeneous nature of these programs and the
resources required for implementation.
Outreach
The outreach component strategy consists of activities that are
triggered when a patient becomes disengaged from clinic. First
the patient is traced to determine his or her vital status. Then, if
tracing is successful and the patient is alive, attempts are made
to relink the individual to the treating health facility. Importantly,
the outreach component has no impact on the rate at which loss
from clinic or care is experienced [10,28–31].
Base-Case Analyses
We compared the effects of alternative retention-in-care strategies
on HIV-positive patients enrolled in care and treatment programs.
We sought to identify the relative impact and cost-effectiveness of
the two interventions independently in comparison to a base case
of either 1) standard of care (null) scenario in which no additional
retention-focused interventions were implemented or 2) a sce-
nario in which ART is scaled up and available for all patients with
a CD4 count of 350 cells/mm3 or less. We used the model to predict
several outcomes, including life expectancy, quality-adjusted life-
years (QALYs), and per-patient total costs for care and treatment.
We estimated the health beneﬁts as the difference between the
life expectancy and QALYs for simulations conducted under either
base-case assumption or with those under the simulated imple-
mentation of a particular retention-in-care strategy. To estimate
the cost-effectiveness, we calculated incremental cost-
effectiveness ratios (ICERs), which represent the difference in costs
divided by the difference in effectiveness of the base-case and
intervention strategies. Costs are reported in 2014 US$, and both0
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Fig. 2 – (A) Recalibration of survival, (B) time to ﬁrst ART regime
compared with clinical data from a large cohort in East Africa (A
ART, antiretroviral treatment.costs and QALYs are discounted at a rate of 3% annually. We
evaluated the cost-effectiveness of the interventions considered
from a payer perspective.
As a supplement to our opportunity-cost–based criteria, WHO
guidelines were also used to deﬁne thresholds for cost-
effectiveness. According to these guidelines, an ICER of less than
one time the per-capita gross domestic product (GDP) ($1000 for
Kenya was used in this analysis [32]) is considered to be “very
cost-effective,” while an ICER of less than three times the per-
capita GDP ($3000) is considered to be “cost-effective” [33].
Given the limitations with precision associated with any simu-
lation, we assumed that an ICER of more than ﬁve times the per-
capita GDP ($5000) would almost certainly be considered unfav-
orable from a decision-making perspective, whereas an ICER
between three and ﬁve times the per-capita GDP may still be
favorable accounting for these limitations.
Sensitivity Analyses
We varied key parameters (see Table 1) in a one-way sensitivity
analysis across a plausible range of values to estimate which
had the strongest effect on the cost-effectiveness, including
the rates associated with disengagement, the efﬁcacy and costs
of the intervention components, and the costs of ART and
routine care. We then conducted multivariate sensitivity anal-
yses using inﬂuential variables derived from the one-way
sensitivity analysis to explore the conditions in which the
intervention value may be enhanced or conditions in which
the implementation of the intervention would be a cost-
effective addition to increasing ART access (i.e., expansion of
earlier ART access to all HIV-infected persons with a CD4 count
of r350 cells/mm3).Results
Calibration of Simulation
We prespeciﬁed the following three calibration criteria to eval-
uate whether the model’s predictions were compatible with4 5 6 7
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Table 2 – Impact and cost-effectiveness of an intervention aimed at reducing attrition (LTFU) within an East
African HIV treatment program.
Intervention Life-years QALY* Costs ($)* ICER ($)
No intervention 14.4 8.8 10,900 –
LTFU risk reduction 15.6 9.4 13,100 (3,700)†
Full coverage of ART (CD4 r 350 cells/mm3) 18.2 10.7 14,800 2,000
LTFU risk reduction þ full ART coverage 19.6 11.3 17,600 4,700
ART, antiretroviral therapy; ICER, incremental cost-effectiveness ratio; LTFU, loss to follow-up; QALY, quality-adjusted life-year.
* Discounted at a rate of 3%.
† Intervention is “weakly dominated” by the next most expensive intervention option (i.e., risk reduction intervention delivers health beneﬁts
for more dollar per QALY [less efﬁciently] than full coverage of ART to all persons with a CD4 count of r350 cells/mm3).
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 4 6 – 9 5 5950observed results: mortality, time to ART regimen failure, and
mean change in CD4 count (after ART initiation) (Fig. 2). We
compared data from time trends over which data were available
(2002–2010) for the criteria.
Effects on Life Expectancy of Disengagement from Care
The projected mean life expectancy for an HIV-infected adult
who remains fully engaged in care is 16.0 years (9.5 QALYs).
When the possibility of disengagement from clinic is considered,
the mean life expectancy decreases to 14.4 years (8.8 QALYs), a
reduction of 1.6 years (0.7 QALYs).
Impact and Cost-Effectiveness of Retention-in-Care-Focused
Interventions
The standard of care (null) scenario results in an average of 14.4
life-years, or 8.8 QALYs, with mean per-person discounted costs
of $10,900. Implementing the risk reduction strategy adds a mean
of 1.2 life-years, or 0.6 QALYs, at a mean incremental cost of
$2,200 to yield an ICER of $3,700/QALY (compared with null
scenario) (Table 2). Implementing an outreach intervention adds
a mean of 0.1 life-year, or 0.1 QALY, at a mean incremental cost of
$100 to yield an ICER of $1,000/QALY. Because the implementa-
tion of this intervention had minimal health impacts and its
inclusion in a combined retention package had no impact on
cost-effectiveness results (data not shown), this component was
not included in further multivariate sensitivity analyses. In
comparison, ensuring complete expansion of ART treatment to
all HIV-infected persons with CD4 counts of 350 cells/mm3 or less
in line with previously adopted WHO guidelines (without any
retention-focused interventions) results in the addition of a mean
of 3.8 life-years, or 2.9 QALYs, at a mean incremental cost of
$3,900 to yield an ICER of $1,300/QALY.
Cost-Effectiveness of Implementation of a Retention-in-Care-
Focused Intervention
We explored the impact of key parameters in the simulation on
the health beneﬁts, cost, and value of retention-in-care inter-
vention by varying their values across plausible ranges. When we
varied parameters independently (i.e., one-way sensitivity anal-
ysis), the strongest inﬂuencers on the value of a retention-
focused intervention, in order of importance, were 1) the cost of
the retention-in-care intervention, 2) the risk of an HIV patient
becoming disengaged from clinic (LTFU), and 3) the likelihood
that a patient classiﬁed as LTFU was no longer connected to care
(see Appendix Fig. 3 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2015.09.2940 ). Importantly, in the scenarios
that we evaluated there were none in which the ICERs for the
retention-in-care intervention were favorable (i.e., less than) than
the ICERs for earlier ART treatment (at a CD4 count ofr350 cells/
mm3). If we assume, however, that all individuals who are LTFUare truly disengaged from care (rather than a proportion remain-
ing connected to care) and that such patients do not return to
care, the cost-effectiveness of the retention-focused intervention
approaches that of the ART expansion (see Appendix Fig. 4 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2015.09.2940).
We evaluated in a multivariate sensitivity analysis scenarios
that may result in cost-effective implementation of the retention-
in-care intervention. When the monthly costs per patient were
assumed to be $1 (or less), the ICER of the retention-in-care
intervention was favorable ($3000 or less) even if the interven-
tion’s efﬁcacy was assumed to be only mild (10% reduction) and
as long as the likelihood of disengagement from clinic was
greater than or equal to initial assumptions (Fig. 3). Even at an
efﬁcacy of 90% and a high probability of disengagement from
both clinic and care, the ICER of the retention-focused interven-
tion, however, was less favorable than that of the earlier ART
initiation (i.e., cost effectiveness ratio of 4$1300). When the
monthly costs per patient were assumed to be $40 or more, there
were no scenarios in which the ICER was less than $3000. When
the monthly costs per patient were between $1 and $40, the
likelihood of the ICER remaining favorable was associated with
an increasing probability of disengagement from clinic, an
increasing probability of disengagement from care, and an
increasing efﬁcacy of the intervention.Value of Retention-in-Care Package as Next Prioritized
Intervention
Given that under the model assumptions there was no scenario
in which a retention-in-care-focused intervention was more
favorable than earlier ART provision from a population health
or economic perspective, we explored under what conditions this
intervention should be prioritized as the next best intervention (i.
e., the addition of retention-focused intervention to earlier ART
provision retains an ICER that is considered favorable/cost-
effective). When the retention-in-care intervention costs were
assumed to be $1 (or less), the ICER of the retention-in-care
intervention was favorable even if the intervention’s efﬁcacy was
assumed to be only mild (10% reduction) and as long as the
likelihood of disengagement from clinic was at least 50% greater
than initial assumptions and the probability of disengagement
from care was greater than 42% (Fig. 4). When the retention-in-
care intervention monthly costs per patient were assumed to be
greater than or equal to $40, the ICER was almost always at least
ﬁve times the per-capita GDP of Kenya ($5000) and not likely to
be favorable. When the monthly costs per patient were between
$1 and $40, the likelihood of the retention-in-care intervention
being a favorable next implementation option was associated
with an increasing probability of disengagement from clinic, an
increasing probability of disengagement from care, and an
increasing efﬁcacy of the intervention.
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Fig. 3 –Multivariate sensitivity analysis of critical factors inﬂuencing cost-effectiveness of a retention-in-care intervention. For
each surface plot, the x-axis represents the probability of no connection to care (i.e., disengaged from care) given the patient is
disengaged from clinic. The y-axis represents multiplier on initial estimate of disengagement from clinic rates. The z-axis
represents incremental cost-effectiveness ratio (ICER; $/quality-adjusted life-year gained) comparing intervention to null
scenario (no retention intervention). Rows of plots represent simulations in which values for effectiveness of risk reduction
intervention are varied and include 10%, 40%, 70%, and 90% risk reduction of disengagement from clinic. Columns of plots
represent simulations in which values for cost of intervention are varied and include $1, $10, $20, $40, and $50 per person
per month. (Color version of ﬁgure available online).
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Fig. 4 – Multivariate analysis of the estimated value of adding a retention-in-care intervention to earlier ART. For each 5  5
grid, rows represent varying assumptions on the probability of no connection to care (i.e., disengaged from care) given the
patient is disengaged from clinic and columns represent varying assumptions on the multiplier on initial estimate of the rates
of disengagement from clinic. Rows of 5  5 grids represent simulations in which values for effectiveness of risk reduction
intervention are varied and include 10%, 40%, 70%, and 90% relative risk reduction of disengagement from clinic. Columns of 5
 5 grids represent simulations in which values for cost of intervention are varied and include $1, $10, $20, $40, and $50 per
person per month. Each cell is color-coded to represent whether the addition of the retention-in-care intervention to full
coverage of an earlier ART policy (at a CD4 count of r350 cells/mm3) would have been favorable from an economic
perspective. Cells shaded green represent an ICER of less than $3000 (o3 the per-capita GDP), cells shaded orange represent
an ICER of $3000 to $5000 (3–5 the per-capita GDP), and cells shaded red represent an ICER of more than $5000 (45 the
per-capita GDP). ART, antiretroviral treatment; GDP, gross domestic product; ICER, incremental cost-effectiveness ratio; RR,
risk ratio. (Color version of ﬁgure available online).
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Using a computer simulation of HIV disease progression and
retention-in-care dynamics in East Africa, we found that disen-
gagement from care had a clinically relevant effect on life
expectancy—an average loss of 1.6 years (0.7 QALYs). In addition,
an intervention designed to improve retention-in-care increased
QALYs compared with no intervention. An outreach intervention
(i.e., physical tracing and relinking) alone was associated with
both minimal costs and minimal beneﬁts under our initial
assumptions. A risk reduction strategy had a more pronounced
impact on clinical outcomes (greater increase in QALYs) when
compared with an outreach strategy. This strategy, however, was
a more expensive intervention.
We found that the factors with the strongest inﬂuence on the
value of a retention-in-care intervention included the risk of
disengagement from clinic (LTFU), the risk of loss of connection
to care if disengaged, and the effectiveness and cost of the
intervention. Under conditions in which the cost is one-tenth of
initial estimates and the risk reduction intervention at least as
efﬁcacious as initially assumed, implementation of retention-in-
care intervention would be a cost-effective use of resources.
Furthermore, if costs exceed $40 per month per person, such an
intervention is unlikely to achieve cost-effectiveness regardless
of other parameter values.
Another key ﬁnding of our analysis is that where resources
are limited, investing in retention-in-care-focused interventions
may be less preferable when “benchmarked” to other potential
HIV care and treatment options, including earlier ART initiation
(at a CD4 count of r350 cells/mm3 instead of r200 cells/mm3).
Our results demonstrate that the value (i.e., the health beneﬁt for
resource expended) of earlier ART treatment is greater than that
of the implementation of the retention-in-care strategies we
considered (and no improvement in ART access). This is likely a
function of our conservative assumptions regarding the propor-
tion of persons classiﬁed as LTFU who are truly disengaged from
care (i.e., only about 25%), the likelihood of these individuals
returning to care (all will return if they become symptomatic),
and the assumption that the cost of the intervention is borne by
all individuals whether or not they are or become lost. In
scenarios in which these assumptions were substantially relaxed,
the retention-focused intervention is on par in terms of value
with earlier ART treatment, and in some cases (i.e., very low cost
or very high efﬁcacy) it may even provide greater health beneﬁts
on average (see Appendix Fig. 4). Similarly, relaxing these
assumptions improves the overall value of a retention-in-care
intervention whereby it is cost-effective (ICER r $3000) across a
much broader array of intervention cost and efﬁcacy values than
under the initial assumptions of our analysis. Under our initial
assumptions, however, scenarios may exist in which the imple-
mentation of retention-in-care package would be a valuable next
strategy following full implementation of earlier ART therapy for
HIV-infected persons seeking care.
In our multivariate sensitivity analysis if the cost of the
intervention is less than $10 per person per month, it may have
favorable value under some conditions (i.e., cost-effective by
compared WHO standards). Furthermore, if the cost could be
brought below $1, it would likely be considered cost-effective and
it would be a preferred next option following scale-up of earlier
ART therapy if implemented in an environment in which LTFU
rates are high and in which many of those classiﬁed as lost were
actually disengaged from care. For instance, in settings in which
robust electronic medical records have been implemented, or in
which ART passports are commonly used, silent transfers are less
common [34] and patients classiﬁed as LTFU are more likely to be
either deceased or alive and disengaged from care. Strategiesaimed at improving retention in this setting would provide
greater health beneﬁts and do so more efﬁciently than in a
setting in which such information and tracking systems do not
exist because, all else being equal, fewer persons would experi-
ence the health beneﬁts of the intervention (maintenance of viral
suppression as a result of robust ART compliance) as a result of
the increased likelihood of misclassiﬁcation. Although our sim-
ulation was not designed to evaluate how such information
systems and other physical tracking systems might affect these
decisions or how they might assist with prioritization of such
interventions, it has brought up important questions for future
study.
Our results are somewhat different from another published
cost-effectiveness study that demonstrated that strategies for
LTFU prevention could result in a substantial saving of life-years
and be considered “very cost-effective” under many scenarios
[35]. If the effectiveness of that study’s intervention (equivalent
to the risk reduction strategy in our study) was at least 41%, it
would be considered “cost-effective” under the cost assumptions
most similar to ours, whereas implementation of this interven-
tion in our model results in an ICER of more than three times the
per-capita GDP. The other study, however, did not account for the
fact that signiﬁcant proportions of persons categorized as LTFU
may remain connected to care and therefore dilute the health
beneﬁts observed for the resources invested in a retention-
focused program.
There is a growing body of evidence that provides insight into
the underlying causes and factors contributing to the poor
retention-in-care experiences of many HIV care and treatment
programs in the developing world [31,36–41]. Patients’ out-of-
pocket expenses for opportunistic infection prophylaxis or ART
and transportation costs/distance from a health center have been
shown to be associated with disengagement in Africa and
poorer clinical outcomes. In addition, interventions to alleviate
these costs to patients have been demonstrated to improve
adherence and retention in care [15,42,43]. Further research
would be useful in assisting decision makers in tailoring and
prioritizing strategies aimed at alleviating and ameliorating these
barriers.
Limitations and Strengths
Our study included several limitations. We did not include the
downstream effects of preventing patients from disengaging
from care or relinking disengaged patients to treatment such as
reduced HIV transmission. Including secondary infections may
have made our results even more favorable to a retention-in-care
portfolio of interventions because maintaining a low VL greatly
reduces the risk of transmission [44,45]. We modeled only two
sequential available ART regimens. It is, however, difﬁcult to
ascertain the magnitude and direction of bias this assumption
has on our results. Whenever possible, we derived model inputs
from East Africa data, but when local data estimates were
unavailable, we used data from elsewhere in sub-Saharan Africa.
Finally, we compared the clinical effectiveness and cost-
effectiveness of only two broad HIV interventions (expansion of
ART access and mitigation of disengagement from care), whereas
broader portfolios of interventions may be under consideration.
A notable strength of our analysis, however, is that it resolves
a shortcoming of previous work: a person categorized as LTFU
may not actually be disengaged from the health care system
(i.e., may have died or may be receiving treatment elsewhere) and
therefore may not derive any health beneﬁts for the resources
invested in the efforts to retain the person. Not considering
this important circumstance would likely result in overestima-
tion of the cost-effectiveness of retention-in-care-focused
interventions.
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Our results suggest that programs should scale up or optimize
their retention programs if they have already achieved broad,
early ART coverage among their HIV-infected population. Under
conditions in which LTFU is common, disengagement from care
is likely and retention programs can be scaled up relatively
inexpensively and this may be a valuable next option on the
implementation “menu” for policymakers and decision makers in
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